我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Minimally Invasive Resection of Gastric Gists: A Laparo-endoscopic Solution

Marano Luigi, Porfidia Raffaele, Reda Gianmarco, Grassia Michele, Petrillo Marianna, Esposito Giuseppe, Braccio Bartolomeo, Pezzella Modestino, Gallo Pierluigi, Romano Angela and Di Martino Natale

Although the feasibility of minimally invasive resections of gastric gastrointestinal stromal tumors (GISTs) has been established, many aspects of this approach are still debated: in different scientific papers, gastroscopy during laparoscopy seems to be an effective technique for successful intraoperative tumor identification. 9 patients were referred to our institution for gastric GISTs. Preoperative work-up for all patients included medical history, standard blood tests, upper gastrointestinal endoscopy with endoscopic ultrasound examination and computed tomography scan. One of these patients underwent open surgery for acutely presentation (haemorrhage), and the other 8 underwent laparoscopic-endoscopic “rendez-vous” resection. The average operative time was 134.1 ± 59.3 min. The mean estimated blood loss was less than 62 ml (range, 10-174 ml). There were no episodes of tumor rupture or spillage, no major intraoperative complications and a conversion rate of 25%. At a mean follow-up of 25 months (range, 3-41) all patients are alive and disease free. There were no local recurrences. Given these findings, a minimally invasive approach should be the preferred surgical treatment in patients with small and medium-sized gastric GIST; moreover a selective approach to laparoscopic resection based on tumor location allows safe resection of these tumors with low morbidity and no compromise of oncologic principles.